The unwell patient with advanced chronic liver disease: when to use each score?

Abstract Background Prognostication in chronic liver disease and the implementation of appropriate scoring systems is difficult given the variety of clinical manifestations. It is important to understand the limitations of each scoring system as well as the context and patient group from which it wa...

Full description

Saved in:
Bibliographic Details
Main Authors: Oliver Moore, Wai-See Ma, Scott Read, Jacob George, Golo Ahlenstiel
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12916-025-04185-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235100682682368
author Oliver Moore
Wai-See Ma
Scott Read
Jacob George
Golo Ahlenstiel
author_facet Oliver Moore
Wai-See Ma
Scott Read
Jacob George
Golo Ahlenstiel
author_sort Oliver Moore
collection DOAJ
description Abstract Background Prognostication in chronic liver disease and the implementation of appropriate scoring systems is difficult given the variety of clinical manifestations. It is important to understand the limitations of each scoring system as well as the context and patient group from which it was developed to allow appropriate application. This review seeks to explore the optimal clinical uses of different predictive scores developed for compensated and decompensated chronic liver disease, acute on chronic liver failure, and hepatocellular carcinoma. We will also review future areas of research for each score and current gaps in the literature. Main body The Child–Pugh score is the pre-eminent prediction score for liver disease that was developed through empiric selection of relevant variables. It is useful for selection of patients for surgical resection of hepatocellular carcinoma but is inferior to other scores for other clinically relevant endpoints such as survival in acute decompensations. The Model for End-Stage Liver Disease (MELD) score and subsequent variants (MELD-Na, MELD 3.0) were developed to predict mortality following elective transjugular intrahepatic portosystemic shunt (TIPS) insertion. An alternative is the Frieberg Index of Post-TIPS Survival (FIPS) score, which has been externally validated for TIPS populations. Organ allocation for liver transplantation is also currently prioritised using the MELD score, with the MELD 3.0 reducing waitlist gender discrepancies. The Chronic Liver Failure Consortium (CLIF-C) acute decompensation (AD) and acute-on-chronic liver failure (ACLF) scores are used for predicting mortality in cirrhotic patients with acute decompensation of liver disease and acute-on-chronic liver failure, respectively. Both scores were developed from retrospective analyses of an observational European cohort with external validation. Understanding of ACLF presentation of advanced liver disease remains in the preliminary stages. Improving collective understanding is important to optimise prognostication. The albumin-bilirubin score is a non-invasive predictor of survival in patients with hepatocellular carcinoma. Incorporating artificial intelligence to personalise predictive algorithms may provide the most effective prognostication for all clinical phenotypes. Conclusion We summarised key prognostic scores used in advanced liver disease and make recommendations for the optimal uses. Nuances in the development and implementation of each are discussed to help guide effective use.
format Article
id doaj-art-8f7b9b2cd656497c8454ecbc54578838
institution Kabale University
issn 1741-7015
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series BMC Medicine
spelling doaj-art-8f7b9b2cd656497c8454ecbc545788382025-08-20T04:02:55ZengBMCBMC Medicine1741-70152025-07-0123111410.1186/s12916-025-04185-wThe unwell patient with advanced chronic liver disease: when to use each score?Oliver Moore0Wai-See Ma1Scott Read2Jacob George3Golo Ahlenstiel4Blacktown Clinical School, School of Medicine, Western Sydney UniversityBlacktown Clinical School, School of Medicine, Western Sydney UniversityBlacktown Clinical School, School of Medicine, Western Sydney UniversityStorr Liver Centre, The Westmead Institute for Medical Research, University of SydneyBlacktown Clinical School, School of Medicine, Western Sydney UniversityAbstract Background Prognostication in chronic liver disease and the implementation of appropriate scoring systems is difficult given the variety of clinical manifestations. It is important to understand the limitations of each scoring system as well as the context and patient group from which it was developed to allow appropriate application. This review seeks to explore the optimal clinical uses of different predictive scores developed for compensated and decompensated chronic liver disease, acute on chronic liver failure, and hepatocellular carcinoma. We will also review future areas of research for each score and current gaps in the literature. Main body The Child–Pugh score is the pre-eminent prediction score for liver disease that was developed through empiric selection of relevant variables. It is useful for selection of patients for surgical resection of hepatocellular carcinoma but is inferior to other scores for other clinically relevant endpoints such as survival in acute decompensations. The Model for End-Stage Liver Disease (MELD) score and subsequent variants (MELD-Na, MELD 3.0) were developed to predict mortality following elective transjugular intrahepatic portosystemic shunt (TIPS) insertion. An alternative is the Frieberg Index of Post-TIPS Survival (FIPS) score, which has been externally validated for TIPS populations. Organ allocation for liver transplantation is also currently prioritised using the MELD score, with the MELD 3.0 reducing waitlist gender discrepancies. The Chronic Liver Failure Consortium (CLIF-C) acute decompensation (AD) and acute-on-chronic liver failure (ACLF) scores are used for predicting mortality in cirrhotic patients with acute decompensation of liver disease and acute-on-chronic liver failure, respectively. Both scores were developed from retrospective analyses of an observational European cohort with external validation. Understanding of ACLF presentation of advanced liver disease remains in the preliminary stages. Improving collective understanding is important to optimise prognostication. The albumin-bilirubin score is a non-invasive predictor of survival in patients with hepatocellular carcinoma. Incorporating artificial intelligence to personalise predictive algorithms may provide the most effective prognostication for all clinical phenotypes. Conclusion We summarised key prognostic scores used in advanced liver disease and make recommendations for the optimal uses. Nuances in the development and implementation of each are discussed to help guide effective use.https://doi.org/10.1186/s12916-025-04185-wLiverCirrhosisChild–PughMELDHepatocellular carcinomaACLF
spellingShingle Oliver Moore
Wai-See Ma
Scott Read
Jacob George
Golo Ahlenstiel
The unwell patient with advanced chronic liver disease: when to use each score?
BMC Medicine
Liver
Cirrhosis
Child–Pugh
MELD
Hepatocellular carcinoma
ACLF
title The unwell patient with advanced chronic liver disease: when to use each score?
title_full The unwell patient with advanced chronic liver disease: when to use each score?
title_fullStr The unwell patient with advanced chronic liver disease: when to use each score?
title_full_unstemmed The unwell patient with advanced chronic liver disease: when to use each score?
title_short The unwell patient with advanced chronic liver disease: when to use each score?
title_sort unwell patient with advanced chronic liver disease when to use each score
topic Liver
Cirrhosis
Child–Pugh
MELD
Hepatocellular carcinoma
ACLF
url https://doi.org/10.1186/s12916-025-04185-w
work_keys_str_mv AT olivermoore theunwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT waiseema theunwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT scottread theunwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT jacobgeorge theunwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT goloahlenstiel theunwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT olivermoore unwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT waiseema unwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT scottread unwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT jacobgeorge unwellpatientwithadvancedchronicliverdiseasewhentouseeachscore
AT goloahlenstiel unwellpatientwithadvancedchronicliverdiseasewhentouseeachscore